Overview

TPI 287 in Breast Cancer Metastatic to the Brain

Status:
Completed

Trial end date:
2017-04-14

Target enrollment:

Participant gender:

Summary

The goal of the first part of this clinical research study is to find the highest tolerable dose of TPI-287 in patients with breast cancer that has spread to the brain. The goal of the second part of this study is to learn if TPI-287 can control breast cancer that has spread to the brain. The safety of this drug will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Cortice Biosciences, Inc.

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Diphenhydramine
Promethazine
Ranitidine
Ranitidine bismuth citrate